200 related articles for article (PubMed ID: 35076335)
1. Mechanisms of Reduced Susceptibility to Cefiderocol Among Isolates from the CREDIBLE-CR and APEKS-NP Clinical Trials.
Nordmann P; Shields RK; Doi Y; Takemura M; Echols R; Matsunaga Y; Yamano Y
Microb Drug Resist; 2022 Apr; 28(4):398-407. PubMed ID: 35076335
[TBL] [Abstract][Full Text] [Related]
2. Occurrence of High Levels of Cefiderocol Resistance in Carbapenem-Resistant Escherichia coli before Its Approval in China: a Report from China CRE-Network.
Wang Q; Jin L; Sun S; Yin Y; Wang R; Chen F; Wang X; Zhang Y; Hou J; Zhang Y; Zhang Z; Luo L; Guo Z; Li Z; Lin X; Bi L; Wang H
Microbiol Spectr; 2022 Jun; 10(3):e0267021. PubMed ID: 35481835
[TBL] [Abstract][Full Text] [Related]
3. Prospective role of cefiderocol in the management of carbapenem-resistant Acinetobacter baumannii infections: Review of the evidence.
Kollef M; Dupont H; Greenberg DE; Viale P; Echols R; Yamano Y; Nicolau DP
Int J Antimicrob Agents; 2023 Aug; 62(2):106882. PubMed ID: 37301312
[TBL] [Abstract][Full Text] [Related]
4. Cefiderocol, a New Siderophore Cephalosporin for the Treatment of Complicated Urinary Tract Infections Caused by Multidrug-Resistant Pathogens: Preclinical and Clinical Pharmacokinetics, Pharmacodynamics, Efficacy and Safety.
Lee YR; Yeo S
Clin Drug Investig; 2020 Oct; 40(10):901-913. PubMed ID: 32700154
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.
Bassetti M; Echols R; Matsunaga Y; Ariyasu M; Doi Y; Ferrer R; Lodise TP; Naas T; Niki Y; Paterson DL; Portsmouth S; Torre-Cisneros J; Toyoizumi K; Wunderink RG; Nagata TD
Lancet Infect Dis; 2021 Feb; 21(2):226-240. PubMed ID: 33058795
[TBL] [Abstract][Full Text] [Related]
6. Outcomes with Cefiderocol Treatment in Patients with Bacteraemia Enrolled into Prospective Phase 2 and Phase 3 Randomised Clinical Studies.
Paterson DL; Kinoshita M; Baba T; Echols R; Portsmouth S
Infect Dis Ther; 2022 Apr; 11(2):853-870. PubMed ID: 35184255
[TBL] [Abstract][Full Text] [Related]
7. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
8. Cefiderocol: A New Cephalosporin Stratagem Against Multidrug-Resistant Gram-Negative Bacteria.
Ong'uti S; Czech M; Robilotti E; Holubar M
Clin Infect Dis; 2022 Apr; 74(7):1303-1312. PubMed ID: 34492098
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study).
Kazmierczak KM; Tsuji M; Wise MG; Hackel M; Yamano Y; Echols R; Sahm DF
Int J Antimicrob Agents; 2019 Feb; 53(2):177-184. PubMed ID: 30395986
[TBL] [Abstract][Full Text] [Related]
10. Evidence for Efficacy of Cefiderocol against OXA-48-Containing Isolates from the APEKS-NP and CREDIBLE-CR Trials.
Longshaw C; Roger E; Santerre Henriksen A; Baba T; Nguyen S; Yamano Y
Antimicrob Agents Chemother; 2022 Oct; 66(10):e0110022. PubMed ID: 36094308
[No Abstract] [Full Text] [Related]
11. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial.
Wunderink RG; Matsunaga Y; Ariyasu M; Clevenbergh P; Echols R; Kaye KS; Kollef M; Menon A; Pogue JM; Shorr AF; Timsit JF; Zeitlinger M; Nagata TD
Lancet Infect Dis; 2021 Feb; 21(2):213-225. PubMed ID: 33058798
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of the novel siderophore cephalosporin, cefiderocol, in Gram-negative pathogens in Europe by site of infection.
Candel FJ; Santerre Henriksen A; Longshaw C; Yamano Y; Oliver A
Clin Microbiol Infect; 2022 Mar; 28(3):447.e1-447.e6. PubMed ID: 34298176
[TBL] [Abstract][Full Text] [Related]
13. Cefiderocol for the Treatment of Infections Due to Metallo-B-lactamase-Producing Pathogens in the CREDIBLE-CR and APEKS-NP Phase 3 Randomized Studies.
Timsit JF; Paul M; Shields RK; Echols R; Baba T; Yamano Y; Portsmouth S
Clin Infect Dis; 2022 Sep; 75(6):1081-1084. PubMed ID: 35148378
[TBL] [Abstract][Full Text] [Related]
14. Characterisation of cefiderocol-non-susceptible Acinetobacter baumannii isolates from Taiwan.
Yamano Y; Ishibashi N; Kuroiwa M; Takemura M; Sheng WH; Hsueh PR
J Glob Antimicrob Resist; 2022 Mar; 28():120-124. PubMed ID: 34958997
[TBL] [Abstract][Full Text] [Related]
15.
Ito A; Sato T; Ota M; Takemura M; Nishikawa T; Toba S; Kohira N; Miyagawa S; Ishibashi N; Matsumoto S; Nakamura R; Tsuji M; Yamano Y
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29061741
[TBL] [Abstract][Full Text] [Related]
16. Activity of Cefiderocol Against
Iregui A; Khan Z; Landman D; Quale J
Microb Drug Resist; 2020 Jul; 26(7):722-726. PubMed ID: 32031915
[TBL] [Abstract][Full Text] [Related]
17. Burkholderia pseudomallei Clinical Isolates Are Highly Susceptible
Burnard D; Robertson G; Henderson A; Falconer C; Bauer MJ; Cottrell K; Gassiep I; Norton R; Paterson DL; Harris PNA
Antimicrob Agents Chemother; 2021 Jan; 65(2):. PubMed ID: 33168603
[TBL] [Abstract][Full Text] [Related]
18. Cefiderocol: a novel siderophore cephalosporin for multidrug-resistant Gram-negative bacterial infections.
Parsels KA; Mastro KA; Steele JM; Thomas SJ; Kufel WD
J Antimicrob Chemother; 2021 May; 76(6):1379-1391. PubMed ID: 33532823
[TBL] [Abstract][Full Text] [Related]
19. Cefiderocol, a new antibiotic against multidrug-resistant Gram-negative bacteria.
Silva JT; López-Medrano F
Rev Esp Quimioter; 2021 Sep; 34 Suppl 1(Suppl1):41-43. PubMed ID: 34598424
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of cefiderocol against clinically important carbapenem non-susceptible Gram-negative bacteria from Saudi Arabia.
Alzayer M; Alghoribi MF; Alalwan B; Alreheli A; Aljohani S; Bosaeed M; Doumith M
J Glob Antimicrob Resist; 2023 Mar; 32():176-180. PubMed ID: 36481491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
